Boston-based Pear discovers, develops, and commercializes Prescription Digital Therapeutics to treat diseases with high unmet need. Founded by Corey McCann, Stephen Smith, and William Greene in 2013, Pear Therapeutics is backed by investors that include 5AM Ventures, Arboretum Ventures, EDBI, Novartis, and Temasek Holdings.